| Objective:Nowadays, for the treatment of chronic hepatitis B, there are five kinds of drugs have gained FDA licenses respectively, which are adefovir, entecavir, pegylated interferon a-2a, and telbivudine tenofovir. The undesirable effect of interferon administration and inconvenience have limited its widespread use. Nucleoside drugs as a new hepatitis B virus inhibitor, has broad application prospects. In this study, a systematic review of different doses of LB80380had assessed,to find out its efficacy, safety and timeliness; quality of hepatitis systematic Reviews/Meta analysis had also assessed which were published in Chinese journal.Methods:According to Cochrane Handbook5.2recommended method to retrieve the relevant database systems as follows,PubMed, EMbase, Cochrane Library, Web of Science, CNKI, Wan fang Database,VIP, CBMdise.The retrieve range was from the beginning of database to January30,2014,collected global LB80380treatment of CHB randomized or quasi-randomized trials. According to the guide of Cochrane systematic, the gained studies were reviewed by two reviewers independently,title and summary,after the exclusion of significant tests which did not meet the inclusion criteria,read the full text which might be the trial that meet the inclusion criteria, then cross-checked by a third-party researcher or seek for suggestion when solving disagreements, so that proceeding Meta-analysis and qualitative analysis for the research results. Meta-analysis process was used by the Cochrane Collaboration RevMan5.2software, fixed effect model or random effect model was chosen according to the heterogeneity test results, test level was α=0.05, the comprehensive evaluation index was estimated95%confidence interval.Aspects of methodological quality and its influencing factors analysis of hepatitis intervention systematic review/Meta analysis published in Chinese magazine, including CNKI, Wan fang Database,VIP, CBMdise, to extract the basic information included in the literature, preferred reporting items for systematic reviews and Meta-Analyses (PRISMA) was used for the quality assessment, SPSS13.0software was used for statistical analysis.Results:The systematic review intook5published literatures,including406cases of CHB patients.Meta-analyses showed that the reduction rate of blood HBV DNA in patients receiving LB8038030mg/d was significantly lower than thatin patients receiving LB8038060,90,150,240mg/d[MD=-0.45,95%CI(-0.89,-0.00),P=0.05];[MD=-0.75,95%CI(-1.19,-0.31),P=0.0009];[MD=-0.94,95%CI(-1.40,-0.47),P<0.0001];[MD=-0.80,95%CI(-1.19,-0.42),P<0.0001].The reduction rate of blood HBV DNA in patients receiving LB8038060mg/d was significantly lower than that in patients receiving LB80380150mg/d[MD=-0.50,95%CI(-0.98,-0.02),P=0.04],while no significant differences were noted between other control groups.There is no statistical differences in creatinine clearance rate among different doses of LB80380and with entecavir0.5mg/d.The study of methodological quality and impact factors of hepatitis intervention Meta analysis published in Chinese magazine included133documents; chronic hepatitis B and chronic hepatitis C were the main diseases. Meta-analysis of the number of papers published in recent years has increased, but the quality of reporting is generally low, PRISMA score ranged from13.5to24, the average score were20±3.15points.Conclusion:LB8038090,150,240mg/d tend to have a better efficacy and safety profiles compared with LB8038030,60,120mg/d,treated24weeks compares with48weeks,there was no remarkable statistical differences, so as the creatinine clearance rate in every group.Chinese Journal published systematic reviews of hepatitis intervention systematic review or Meta analysis reports were medium quality, the quality of reporting standards and methodological quality need to be improved. |
PDF Full Text Request